Hector Ortega Selected Research

mepolizumab

1/2020	Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
1/2020	Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
1/2019	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
1/2019	Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial.
1/2019	Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
1/2019	Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.
9/2018	Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
7/2018	Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
5/2018	Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.
12/2017	Biomarkers for severe eosinophilic asthma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hector Ortega Research Topics

Disease

30	Asthma (Bronchial Asthma) 01/2022 - 09/2004
3	Inflammation (Inflammations) 01/2020 - 08/2012
3	Infections 01/2020 - 12/2017
3	Eosinophilia 09/2018 - 07/2014
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2019 - 01/2018
2	Chronic Urticaria 01/2019 - 01/2019
1	Pulmonary Hypertension 01/2022
1	Allergic Rhinitis 01/2019
1	Atopic Dermatitis (Atopic Eczema) 01/2019
1	Nasal Polyps (Nasal Polyp) 01/2019
1	Sinusitis 01/2019
1	Disease Progression 01/2019
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 09/2018
1	Airway Remodeling 09/2004

Drug/Important Bio-Agent (IBA)

17	mepolizumabIBA 01/2020 - 08/2012
12	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 06/2008
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2015
3	Biological ProductsIBA 01/2020 - 01/2019
3	Messenger RNA (mRNA)IBA 01/2020 - 12/2017
2	prostaglandin D2 receptorIBA 01/2022 - 01/2020
2	Omalizumab (Xolair)FDA Link 01/2019 - 01/2019
2	Interleukin-5 (Interleukin 5)IBA 09/2018 - 11/2017
2	Monoclonal AntibodiesIBA 11/2017 - 08/2012
2	Genetic Markers (Genetic Marker)IBA 11/2017 - 06/2013
2	GlucocorticoidsIBA 11/2017 - 01/2017
2	Salmeterol Xinafoate (Serevent)FDA Link 07/2008 - 06/2008
1	ORALIT (ORS)IBA 01/2022
1	ProstaglandinsIBA 01/2022
1	lipoarabinomannan (LAM)IBA 01/2020
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020
1	Pharmaceutical PreparationsIBA 07/2016
1	Prednisone (Sone)FDA LinkGeneric 07/2016
1	InterleukinsIBA 08/2012
1	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 07/2008
1	Fluticasone (Cutivate)FDA LinkGeneric 06/2008
1	Albuterol (Salbutamol)FDA LinkGeneric 06/2008

Therapy/Procedure

10	Therapeutics 08/2019 - 09/2004
1	Endarterectomy (Thromboendarterectomy) 01/2022
1	Ambulatory Care (Outpatient Care) 01/2019
1	Biological Therapy 01/2019
1	Drug Therapy (Chemotherapy) 07/2016
1	Precision Medicine 09/2014
1	Critical Care (Surgical Intensive Care) 06/2013